Patient: Page 4
-
Q&A
Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’
The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.
By Michael Gibney • Oct. 19, 2023 -
From the rainforest to Wall Street — Jaguar Health’s big play for revitalization
A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.
By Kelly Bilodeau • Oct. 17, 2023 -
Trendline
Cell and gene therapies
How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.
By PharmaVoice staff -
PharmaVoice 100
PharmaVoice 100s: Rare disease warriors
Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.
By Michael Gibney • Oct. 16, 2023 -
PharmaVoice 100
PharmaVoice 100s: Patient heroes
Leaders innovating new ways to incorporate patient voices in drug development and decrease barriers to access.
By Karissa Waddick • Oct. 13, 2023 -
Opinion
Branded: The trademarks pharma leaders look up to
What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.
By PharmaVoice Staff • Oct. 13, 2023 -
Deep Dive
A decade later, biotech’s CRISPR revolution is still going strong
Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.
By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023 -
Q&A // Biotech Spotlight
To close the pediatric innovation gap, this biotech has to think differently
Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.
By Alexandra Pecci • Oct. 11, 2023 -
3 recent FDA adcomm rejections — and why they matter
Decisions that could spell doom for drugs in development and already on the shelves.
By Meagan Parrish • Sept. 29, 2023 -
Do humans have a place in pharma’s AI future?
From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.
By Michael Gibney • Sept. 26, 2023 -
Elderly exclusion: Clinical trials still fall short enrolling older adults
Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.
By Kelly Bilodeau • Sept. 25, 2023 -
Sponsored by Phil Inc
Optimizing your hub services program with a gross-to-net lens
In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.
Sept. 25, 2023 -
Profile
Three years after an FDA rejection, DBV sees a path for its peanut patch
Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.
By Karissa Waddick • Sept. 22, 2023 -
Q&A
As the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
By Michael Gibney • Sept. 21, 2023 -
What happened to ivermectin?
The saga of the anti-parasitic drug continues.
By Alexandra Pecci • Sept. 20, 2023 -
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
By Julia Himmel • Sept. 19, 2023 -
O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad
The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups.
By Karissa Waddick • Sept. 14, 2023 -
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
By Meagan Parrish • Sept. 13, 2023 -
A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say
A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.
By Alexandra Pecci • Sept. 12, 2023 -
Roz Brewer announces sudden departure as CEO of Walgreens
The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.
By Meagan Parrish • Sept. 1, 2023 -
A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?
Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.
By Meagan Parrish • Sept. 1, 2023 -
Why pharma isn’t done tackling migraines
In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options.
By Kelly Bilodeau • Aug. 28, 2023 -
Henrietta Lacks’ immortal cells put biopharma profits under a microscope
The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.
By Michael Gibney • Aug. 23, 2023 -
Profile
A rare disease researcher aims to tackle disability discrimination in new lawsuit
How a pediatric neurologist is advocating for herself and the disabled community in a legal battle with the Howard Hughes Medical Institute.
By Alexandra Pecci • Aug. 22, 2023 -
Sponsored by Medidata
Leveraging data to drive efficiency and patient-centricity in clinical trials
Using real-time data, patient centricity and personalized medicine to accelerate clinical trials.
By Fareed Melhem, senior vice president and head of Medidata AI. Medidata is a Dassault Systèmes company. • Aug. 21, 2023 -
Demand for weight loss drugs soars to nearly half of Americans
Drugs like the buzzy Ozempic are high on consumers’ radar — but lofty barriers to access remain.
By Alexandra Pecci • Aug. 15, 2023